预约演示
更新于：2025-12-15
Nefopam Hydrochloride
盐酸奈福泮
更新于：2025-12-15
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1985-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20ClNO |
InChIKeyCNNVSINJDJNHQK-UHFFFAOYSA-N |
CAS号23327-57-3 |
关联
108
项与 盐酸奈福泮 相关的临床试验CTIS2025-522389-66-00
Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone)
TCTR20250901008
The efficacy of intermittent intravenous nefopam for postoperative pain control: Randomized Control Trial in robotic assisted-Total Knee Arthroplasty
NCT06627816
Efficacy of Intravenous Nefopam, Dexmedetomidine, and Meperidine in Preventing Post-Spinal Anesthesia Shivering in Adult Patients Undergoing Lower Abdominal and Lower Limb Surgeries: A Double-Blind Comparative Study
100 项与 盐酸奈福泮 相关的临床结果
登录后查看更多信息
100 项与 盐酸奈福泮 相关的转化医学
登录后查看更多信息
100 项与 盐酸奈福泮 相关的专利（医药）
登录后查看更多信息
660
项与 盐酸奈福泮 相关的文献（医药）2025-11-01Anaesthesia Critical Care & Pain Medicine
The application of continuous nefopam infusion in analgesia and sedation for mechanically ventilated patients in the ICU: Authors' reply
Letter
作者: Mukhtar, Ahmed Mohammed ; Farid, Samar Farghali ; Sabry, Nirmeen Ahmed ; Abdelraouf, Mohammed Gamal
2025-10-01Anaesthesia Critical Care & Pain Medicine
Comfort-Focused Assessment and Patient-Reported Experience After Regional versus General Anaesthesia: Post Hoc Analysis of a Cluster-Randomised Trial
Article
作者: Auquier, Pascal ; Rozier, Romain ; Meuret, Ludovic ; Beloeil, Hélène ; Fusco, Nicolas ; Loundou, Anderson ; Maurice-Szamburski, Axel
INTRODUCTION:
Postoperative pain management typically relies on numerical (NRS) or analogue rating scales. However, exclusive focus on nociception may overlook broader aspects of patient experience, especially under regional anaesthesia (RA). This post hoc analysis of the COMFORT trial (NCT05234216) examined whether replacing the NRS with a comfort-focused scale affects patient-reported experience, opioid use, and related outcomes.
METHODS:
We analysed data from a cluster-randomised trial in 29 French centres. Adults undergoing elective non-cardiac surgery managed in the post-anaesthesia care unit (PACU) were included. The intervention (comfort scale) and comparator (pain NRS) were applied in the PACU. Patient-reported experience was measured with the EVAN-G/LR scales, self-completed on the ward/day-care unit ≥4 hours postoperatively. Participants were divided into RA and general anaesthesia subgroups.
RESULTS:
Of 885 randomised patients, 786 had evaluable EVAN data. After regional anaesthesia (RA; n = 305), comfort‑focused assessment was associated with higher EVAN Pain (median 88 [IQR 75-94] vs. 75 [69-88]; p = 0.034), Waiting (100 [75-100] vs. 75 [50-100]; p = 0.012), and Global Index (81 [72-91] vs. 77 [68-90]; p = 0.044). After general anaesthesia (GA; n=481), EVAN scores were similar between groups. Nefopam use was lower with the comfort approach in RA (7% vs. 18%; p = 0.005). Antiemetic use was lower with the comfort approach in GA.
CONCLUSION:
Replacing the NRS with a comfort-focused approach did not improve global patient experience after surgery. In patients receiving regional anaesthesia, however, using a comfort scale was associated with better patient-reported experience in the EVAN "Pain" dimension, while no benefit was observed after general anaesthesia.
2025-10-01JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
Nefopam for Analgesia Following Cardiac Surgery: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Article
作者: Taechawattananan, Nalinpat ; Raykateeraroj, Nattaya ; Lertkovit, Saranya ; Kitisin, Nuanprae ; Saraphang, Saifon ; Vacharaksa, Kamheang ; Kongkanond, Tipkanya ; Subtaweesin, Thaworn ; Weinberg, Laurence
OBJECTIVE:
To evaluate the analgesic efficacy, opioid-sparing effects, and safety profile of nefopam compared with placebo following elective cardiac surgery.
DESIGN:
Randomized, double-blind, placebo-controlled trial at a tertiary care center.
SETTING:
Perioperative care.
PARTICIPANTS:
A total of 103 adults (mean age, 57.9 ± 11.3 years) undergoing elective cardiac surgery via median sternotomy were randomized to receive nefopam (n = 50) or placebo (n = 53).
INTERVENTIONS:
Patients were randomized to receive nefopam (20 mg intravenous [IV] bolus, followed by an 80 mg continuous infusion over 24 hours) or placebo, with both groups receiving standardized IV fentanyl via patient-controlled analgesia.
MEASUREMENTS AND MAIN RESULTS:
The primary outcome was cumulative fentanyl consumption over 48 hours. Secondary outcomes included pain scores (NRS 0-10), intubation duration, intensive care unit (ICU)/hospital length of stay, and adverse events. Both fentanyl consumption and pain scores were assessed at 3, 6, 12, 24, and 48 hours postoperatively. The nefopam group consumed 25% less fentanyl over 48 hours (mean, 16.3 ± 1.6 µg/kg vs 21.9 ± 1.6 µg/kg; p = 0.014), with significant reductions from 6 hours to 48 hours. Pain scores were lower in the nefopam group at rest at 48 hours (p = 0.03) and during movement at 24 and 48 hours (p = 0.04 and 0.01), although overall pain remained mild. Adverse events (eg, sinus tachycardia, agitation/delirium) were comparable in the 2 groups. Duration of intubation and ICU/hospital length of stay did not differ between the 2 groups.
CONCLUSIONS:
Nefopam was well tolerated and associated with statistically significant but clinically modest reductions in fentanyl use and pain scores after cardiac surgery, supporting its role as a safe adjunct in multimodal analgesia.
100 项与 盐酸奈福泮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 韩国 | 2008-06-11 | |
| 术后疼痛 | 韩国 | 2008-06-11 | |
| 疼痛 | 中国 | 1985-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性疼痛 | 临床1期 | 澳大利亚 | 2024-08-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 32 | (FDC Nefopam Hydrochloride 30mg / Paracetamol 500mg) | 淵蓋糧鑰餘範選願獵積(選憲範憲獵築糧鹽鹹齋) = 顧憲鑰鹹齋遞壓獵網選 艱壓構觸夢觸醖憲淵艱 (網遞鑰網鏇獵觸蓋選鏇, 38.283) 更多 | - | 2024-10-31 | |
(Nefopam Hydrochloride 30mg) | 淵蓋糧鑰餘範選願獵積(選憲範憲獵築糧鹽鹹齋) = 鬱遞襯願鏇鏇繭選遞淵 艱壓構觸夢觸醖憲淵艱 (網遞鑰網鏇獵觸蓋選鏇, 40.071) 更多 | ||||||
临床3期 | 40 | 鹽構醖遞鬱繭醖製製夢(鑰顧艱鏇廠蓋艱壓淵簾) = 鹽鏇艱鑰構蓋餘網獵襯 鏇壓選製積壓蓋醖艱獵 (獵鏇獵餘淵醖範襯網膚 ) | - | 2020-01-01 | |||
Placebo | 鹽構醖遞鬱繭醖製製夢(鑰顧艱鏇廠蓋艱壓淵簾) = 窪夢艱衊憲構淵製鏇糧 鏇壓選製積壓蓋醖艱獵 (獵鏇獵餘淵醖範襯網膚 ) | ||||||
N/A | 42 | 齋廠鬱蓋鹹觸構簾選醖(築範夢鹹鑰淵鹹遞遞艱) = 夢膚製鏇鹹鑰蓋網衊衊 鑰鑰簾簾衊壓獵齋鹹廠 (醖鬱築願簾繭網餘獵廠 ) | 积极 | 2016-02-01 | |||
Placebo | 齋廠鬱蓋鹹觸構簾選醖(築範夢鹹鑰淵鹹遞遞艱) = 餘鏇蓋餘鑰簾衊淵憲遞 鑰鑰簾簾衊壓獵齋鹹廠 (醖鬱築願簾繭網餘獵廠 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用